Abstract 55P
Background
Routine methods for MSI/dMMR for CRC pts detection are PCR/IHC, however the data on the benefit of ICI in cases with discordant results is limited. The clinical validity of NGS as a promising approach for MSI detection is currently unclear.
Methods
Patients with MSI+ (PCR) or dMMR (IHC) colorectal cancer (CRC) were eligible (NCT06414304). All patients received immune checkpoint inhibitors (ICI) and had pre-treatment FFPE and liquid biopsy (LB) samples available for central MSI/dMMR testing with PCR/IHC (FFPE) and with NGS (Atlas Pro panel) (FFPE and LB).
Results
A total of 32 patients were included, 22 patients with stages II-III received ICI preoperatively, 10 – for advanced disease; 28 were available for response assessment. ORR in ITT population was 46%. Among 4 patients with discordant results (PCR vs IHC), ORR was 0% (p>0.05). In patients with MSI+ FFPE or MSI+ LB by NGS (n=23), ORR was 57% (p>0.05). Among pts with available LB (n=26), ORR was higher when LB samples were MSI+ (56%) vs MSS (25%) with p>0.05. Among MSI+ by NGS (LB) cases two were pMMR by IHC. Both cases had SD and were MSI+ by PCR and NGS (FFPE). None of the patients had MSI+ by NGS (LB) and MSS by PCR. Patients with DC had a median blood MSI burden of 0.07 (range, 0-0.77), whereas median MSI burden of pts with PD was 3.76 (range, 2.44-5.08) (p=0.03). Table: 55P
ORR by MSI analysis via different methods
| NGS (FFPE) | NGS (FFPE) | NGS (LB) | NGS (LB) | ||
| MSI | MSS | MSI | MSS | ||
| IHC (FFPE) | dMMR | 50% (n=16) | 0% (n=1) | 75% (n=12) | 33% (n=3) |
| IHC (FFPE) | pMMR | 0% (n=3) | n=0 | 0% (n=2) | 0% (n=1) |
| PCR (FFPE) | MSI | 45% (n=20) | 100% (n=1) | 44% (n=16) | 33% (n=3) |
| PCR (FFPE) | MSS | n=0 | 0% (n=1) | n=0 | 0% (n=1) |
Conclusions
Patients with MSI+ by PCR may experience different ICI benefits based on IHC status. Patients with MSI+ LB have better ORR. MSI burden analysis in pre-treatment LB samples is associated with better treatment outcomes. Further research is warranted.
Editorial acknowledgement
Clinical trial identification
NCT06414304.
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (Grant №22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
152P - Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping
Presenter: Khashayar Roohollahi
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - Discovery of new BRCA1/2 mutations not described in the international breast consortium
Presenter: Wala Ben Kridis
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - Alternative splicing in non-small cell lung cancer evolution
Presenter: Michelle Leung
Session: Cocktail & Poster Display session
Resources:
Abstract
155TiP - Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Presenter: Julieta Rodriguez
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - Therapeutic potential of B7-H3 targeting in pediatric neuroblastoma
Presenter: Caroline E Nunes-Xavier
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - E-JIB-04: An epigenetic targeted therapy for ovarian cancer with MECOM amplification
Presenter: Ibha Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - The impact of kisspeptin pre-treatment towards temozolomide resistance mechanisms and associated differently expressed proteins (DEPs) in human glioblastoma cells
Presenter: Isra Sati
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - Clinical observation and immune effects of high-intensity focused ultrasound (HIFU) in the treatment of liver metastasis in colorectal cancer
Presenter: Shasha Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - Early phase cancer clinical trials: A viable treatment option for patients?
Presenter: Rhona Dawson
Session: Cocktail & Poster Display session
Resources:
Abstract
162P - Tailoring patient molecular selection for novel anti-MET therapies
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract